{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:12:52Z","timestamp":1782832372219,"version":"3.54.5"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["NIHR202781"],"award-info":[{"award-number":["NIHR202781"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bullous pemphigoid (BP) is an autoimmune skin disease that mainly affects older people. Based on case series and small hospital-based studies, a number of drugs have been associated with BP. More reliable and precise estimates of associations between a broad selection of drugs\/vaccines and BP will enable greater awareness of any potential increased risk of BP following the administration of certain medicines and help identify clinical, histological and genomic characteristics of drug-induced BP for different culprit drugs. Greater awareness could lead to earlier recognition or suspicion of BP and referral to a dermatologist for diagnosis. Earlier diagnosis may lead to less aggressive treatment and improved wellbeing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the association between drugs\/vaccines commonly prescribed to older people and the risk of developing BP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a population-based nested case\u2013control study between 1998 and 2021 using electronic primary care records from the Clinical Practice Research Datalink. We matched patients with BP with up to five controls. Exposures were drugs\/vaccines commonly prescribed to older people. We used multivariable conditional logistic regression adjusting for multiple drug use. For antibiotics, in a sensitivity analysis, we considered that drugs may be prescribed for undiagnosed symptoms of BP that resemble skin infection (protopathic bias).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Antibiotics were associated with the highest risk of BP [odds ratio (OR) 4.60, 95% confidence interval (CI) 4.40\u20134.80]. However, after adjusting for protopathic bias, the OR decreased to 2.08 (95% CI 1.99\u20132.17). Also, after adjusting for protopathic bias, of all the antibiotic classes and subclasses, penicillins [OR 3.44, 95% CI 3.29\u20133.60 (sensitivity analysis OR 1.74, 95% CI 1.66\u20131.84)] and penicillinase-resistant penicillins [OR 7.56, 95% CI 7.15\u20138.00 (sensitivity analysis OR 2.64, 95% CI 2.45\u20132.85)] had the strongest associations with BP risk. Other drugs strongly associated with increased risk were gliptins (OR 2.77, 95% CI 2.37\u20133.23) and second-generation antipsychotics (OR 2.58, 95% CI 2.20\u20133.03).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Healthcare professionals need to be aware of BP risk in older people, particularly when prescribing penicillinase-resistant penicillins, gliptins and second-generation antipsychotic drugs, to recognize and manage BP early. Owing to the low disease prevalence, we do not suggest avoiding certain drugs\/vaccines to prevent BP. Further research should consider recency, dosage and duration of antibiotic treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae416","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T22:51:23Z","timestamp":1730155883000},"page":"440-449","source":"Crossref","is-referenced-by-count":7,"title":["Association between drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a\u00a0case\u2013control study"],"prefix":"10.1093","volume":"192","author":[{"given":"Mikolaj","family":"Swiderski","sequence":"first","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Vinogradova","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D","family":"Knaggs","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Harman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals of Leicester NHS Trust , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4920-6718","authenticated-orcid":false,"given":"Rowan H","family":"Harwood","sequence":"additional","affiliation":[{"name":"School of Health Sciences, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhore","family":"Prasad","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]},{"name":"King\u2019s College London , London ,","place":["UK"]},{"name":"NHS Nottinghamshire , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica S M","family":"Persson","sequence":"additional","affiliation":[{"name":"Swedish Rheumatism Association , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazziela","family":"Figueredo","sequence":"additional","affiliation":[{"name":"School of Computer Science, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carron","family":"Layfield","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gran","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"2025021810044201200_ljae416-B1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol"},{"key":"2025021810044201200_ljae416-B2","doi-asserted-by":"crossref","first-page":"j2169","DOI":"10.1136\/bmj.j2169","article-title":"Bullous pemphigoid and pemphigus vulgaris","volume":"357","author":"Kayani","year":"2017","journal-title":"BMJ"},{"key":"2025021810044201200_ljae416-B3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B4","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"2025021810044201200_ljae416-B5","doi-asserted-by":"crossref","first-page":"e904\u201311","DOI":"10.3399\/BJGP.2020.0870","article-title":"Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study","volume":"71","author":"Persson","year":"2021","journal-title":"Br J Gen Pract"},{"key":"2025021810044201200_ljae416-B6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1590\/abd1806-4841.20164935","article-title":"Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study","volume":"91","author":"Kouris","year":"2016","journal-title":"An Bras Dermatol"},{"key":"2025021810044201200_ljae416-B7","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/bjd.18731","article-title":"Assessment of healthcare costs for patients with pemphigus and bullous pemphigoid in an academic centre in Germany","volume":"182","author":"Stander","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/bjd.19830","article-title":"Classifying the severity of bullous pemphigoid disease","volume":"184","author":"Blome","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"2025021810044201200_ljae416-B10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allerg Immunol"},{"key":"2025021810044201200_ljae416-B11","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025021810044201200_ljae416-B12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jdermsci.2020.05.010","article-title":"Genetic predisposition to bullous pemphigoid","volume":"100","author":"Zhang","year":"2020","journal-title":"J Dermatol Sci"},{"key":"2025021810044201200_ljae416-B13","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid \u2013 more than skin deep?","volume":"26","author":"Forsti","year":"2017","journal-title":"Exp Dermatol"},{"key":"2025021810044201200_ljae416-B14","first-page":"1305","article-title":"Association between bullous pemphigoid and psychiatric disorders: a systematic review and meta-analysis","volume":"20","author":"Huang","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025021810044201200_ljae416-B15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A","volume":"176","author":"Ren","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025021810044201200_ljae416-B17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case\u2013control study","volume":"149","author":"Lloyd-Lavery","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2025021810044201200_ljae416-B18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025021810044201200_ljae416-B19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","article-title":"Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and-BP230 humoral response: results of a multicenter study","volume":"87","author":"Salemme","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025021810044201200_ljae416-B21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jdi.14004","article-title":"Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: a population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database","volume":"14","author":"Harano","year":"2023","journal-title":"J Diabetes Invest"},{"key":"2025021810044201200_ljae416-B22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","article-title":"Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences","volume":"12","author":"Pazan","year":"2021","journal-title":"Eur Geriatr Med"},{"key":"2025021810044201200_ljae416-B23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2025021810044201200_ljae416-B24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1006\/pmed.1994.1093","article-title":"Nested case\u2013control studies","volume":"23","author":"Ernster","year":"1994","journal-title":"Prev Med"},{"key":"2025021810044201200_ljae416-B25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2288-8-48","article-title":"Advantages of the nested case\u2013control design in diagnostic research","volume":"8","author":"Biesheuvel","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"2025021810044201200_ljae416-B26","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"2025021810044201200_ljae416-B27","article-title":"The association between medicines and vaccines commonly prescribed to older people and bullous pemphigoid: a UK population-based study","author":"Swiderski"},{"key":"2025021810044201200_ljae416-B28","article-title":"Introduction to CPRD","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"2025021810044201200_ljae416-B29","article-title":"Population estimates for the UK, England, Wales, Scotland, and Northern Ireland: mid-2022","author":"Office for National Statistics"},{"key":"2025021810044201200_ljae416-B30","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2025021810044201200_ljae416-B31","doi-asserted-by":"crossref","first-page":"e035934","DOI":"10.1136\/bmjopen-2019-035934","article-title":"Validation study of bullous pemphigoid and pemphigus vulgaris recording in routinely collected electronic primary healthcare records in England","volume":"10","author":"Persson","year":"2020","journal-title":"BMJ Open"},{"key":"2025021810044201200_ljae416-B32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pds.1115","article-title":"The relationship between time since registration and measured incidence rates in the General Practice Research Database","volume":"14","author":"Lewis","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025021810044201200_ljae416-B33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14815","article-title":"Statin use and the risk of herpes zoster: a nested case\u2013control study using primary care data from the U.K. Clinical Research Practice Datalink","volume":"175","author":"Matthews","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B34","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1136\/oem.2004.014472","article-title":"An incidence density sampling program for nested case\u2013control analyses","volume":"61","author":"Richardson","year":"2004","journal-title":"Occup Environ Med"},{"key":"2025021810044201200_ljae416-B35","first-page":"e63\u201377","article-title":"A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service","volume":"1","author":"Kuan","year":"2019","journal-title":"Lancet Digit Health"},{"key":"2025021810044201200_ljae416-B36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"della Torre","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaad.2019.04.029","article-title":"Nonbullous pemphigoid: insights in clinical and diagnostic findings, treatment responses, and prognosis","volume":"81","author":"Lamberts","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025021810044201200_ljae416-B38","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2019"},{"key":"2025021810044201200_ljae416-B39","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archdermatol.2010.322","article-title":"The association of bullous pemphigoid with cerebrovascular disease and dementia: a case\u2013control study","volume":"146","author":"Taghipour","year":"2010","journal-title":"Arch Dermatol"},{"key":"2025021810044201200_ljae416-B40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: a population-based case\u2013control study","volume":"131","author":"Langan","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2025021810044201200_ljae416-B41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid","volume":"307","author":"Alpsoy","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"2025021810044201200_ljae416-B42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case\u2013control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2025021810044201200_ljae416-B43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/STROKEAHA.110.596361","article-title":"Increased risk of stroke in patients with bullous pemphigoid: a population-based follow-up study","volume":"42","author":"Yang","year":"2011","journal-title":"Stroke"},{"key":"2025021810044201200_ljae416-B44","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1684\/ejd.2017.3066","article-title":"The association between bullous pemphigoid and neurological disorders: a systematic review","volume":"27","author":"Milani-Nejad","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2025021810044201200_ljae416-B45","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"key":"2025021810044201200_ljae416-B46","doi-asserted-by":"crossref","first-page":"E857\u201361","DOI":"10.4088\/JCP.15f10150","article-title":"Understanding relative risk, odds ratio, and related terms: as simple as it can get","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"2025021810044201200_ljae416-B47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bcp.12705","article-title":"Indication bias or protopathic bias?","volume":"80","author":"Faillie","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2025021810044201200_ljae416-B48","first-page":"484","article-title":"Blistering skin conditions","volume":"38","author":"Welsh","year":"2009","journal-title":"Aust Fam Physician"},{"key":"2025021810044201200_ljae416-B49","doi-asserted-by":"crossref","first-page":"E107\u201314","DOI":"10.1503\/cmaj.190757","article-title":"Development and validation of the Cambridge Multimorbidity Score","volume":"192","author":"Payne","year":"2020","journal-title":"CMAJ"},{"key":"2025021810044201200_ljae416-B50","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes","volume":"42","author":"Douros","year":"2019","journal-title":"Diabetes Care"},{"key":"2025021810044201200_ljae416-B51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/2042098614523031","article-title":"Safety of dipeptidyl peptidase 4 inhibitors: a perspective review","volume":"5","author":"Karagiannis","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"2025021810044201200_ljae416-B52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","article-title":"Bullous pemphigoid during ustekinumab therapy","volume":"1","author":"Le Guern","year":"2015","journal-title":"JAAD Case Rep"},{"key":"2025021810044201200_ljae416-B53","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/1346-8138.12943","article-title":"Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab","volume":"42","author":"Nakayama","year":"2015","journal-title":"J Dermatol"},{"key":"2025021810044201200_ljae416-B54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-2133.1996.d01-963.x","article-title":"Bullous pemphigoid induced by vaccination","volume":"135","author":"Fournier","year":"1996","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B55","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/000155501317208534","article-title":"Generalized bullous fixed drug eruption after influenza vaccination, simulating bullous pemphigoid","volume":"81","author":"Garcia-Doval","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"2025021810044201200_ljae416-B56","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study","volume":"165","author":"Chen","year":"2011","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B57","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025021810044201200_ljae416-B58","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025021810044201200_ljae416-B59","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jvc2.36","article-title":"Associations among bullous pemphigoid and various neurological diseases: a systematic review and meta-analysis","volume":"1","author":"Chen","year":"2022","journal-title":"JEADV Clin Pract"},{"key":"2025021810044201200_ljae416-B60","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1176\/appi.ajp.163.3.521","article-title":"Association of schizophrenia and autoimmune diseases: linkage of Danish national registers","volume":"163","author":"Eaton","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2025021810044201200_ljae416-B61","doi-asserted-by":"crossref","first-page":"37125","DOI":"10.1038\/srep37125","article-title":"Psychiatric and neurological disorders are associated with bullous pemphigoid \u2013 a nationwide Finnish Care Register study","volume":"6","author":"F\u00f6rsti","year":"2016","journal-title":"Sci Rep"},{"key":"2025021810044201200_ljae416-B62","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1176\/appi.ajp.2013.13010086","article-title":"A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis","volume":"171","author":"Benros","year":"2014","journal-title":"Am J Psychiatry"},{"key":"2025021810044201200_ljae416-B63","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1684\/ejd.2017.3066","article-title":"The association between bullous pemphigoid and neurological disorders: a systematic review","volume":"27","author":"Milani-Nejad","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2025021810044201200_ljae416-B64","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12888-020-02810-x","article-title":"Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers","volume":"20","author":"Rania","year":"2020","journal-title":"BMC Psychiatry"},{"key":"2025021810044201200_ljae416-B65","article-title":"Flu vaccine","author":"National Health Service"},{"key":"2025021810044201200_ljae416-B66","article-title":"In 2021, Trajenta\u00ae marks 10\u2005years since first regulatory approval. But, it took many more years to achieve that milestone","author":"Boehringer Ingelheim"},{"key":"2025021810044201200_ljae416-B67","article-title":"Trajenta","author":"European Medicines Agency"},{"key":"2025021810044201200_ljae416-B68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12963-023-00302-0","article-title":"Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom\u2019s Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES)","volume":"21","author":"Shiekh","year":"2023","journal-title":"Popul Health Metr"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae416\/60179037\/ljae416.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/440\/60179037\/ljae416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/440\/60179037\/ljae416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:05:42Z","timestamp":1739873142000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/3\/440\/7848194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,28]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae416","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,28]]}}}